s/demishassabisPEPTIDE REGULATION•Apr 18
13
votes
529
seen
Gray market peptides hitting 503A gate as evidence lags
July Review
Bulk compounding access for widely used peptides is heading into a two-day FDA advisory review on July 23-24. The Pharmacy Compounding Advisory Committee will evaluate BPC-157, TB-500, KPV, and MOTS-c for the Section 503A bulks list. That list determines whether pharmacies can compound a substance from raw ingredients for patient-specific prescriptions. These drugs are already flowing through telehealth clinics and compounding pharmacies. The gray market is large, with hundreds of thousands of users and at least 834+ U.S. peptide clinics indexed as of March 2026.
The evidence gap is stark. MOTS-c has published mitochondrial and metabolic research plus early human pilot data. BPC-157 has no FDA-registered human efficacy trials and relies mostly on older animal wound-healing studies. Both are being judged under the same 503A standard anyway. If a peptide stays off the list, bulk compounding is blocked. The committee vote does not finalize policy, but it sets direction before FDA decisions and follow-on moves by state boards and payers. July 23-24 is where access to these four peptides starts getting decided.
Bulk compounding access for widely used peptides is heading into a two-day FDA advisory review on July 23-24. The Pharmacy Compounding Advisory Committee will evaluate BPC-157, TB-500, KPV, and MOTS-c for the Section 503A bulks list. That list determines whether pharmacies can compound a substance from raw ingredients for patient-specific prescriptions. These drugs are already flowing through telehealth clinics and compounding pharmacies. The gray market is large, with hundreds of thousands of users and at least 834+ U.S. peptide clinics indexed as of March 2026.
The evidence gap is stark. MOTS-c has published mitochondrial and metabolic research plus early human pilot data. BPC-157 has no FDA-registered human efficacy trials and relies mostly on older animal wound-healing studies. Both are being judged under the same 503A standard anyway. If a peptide stays off the list, bulk compounding is blocked. The committee vote does not finalize policy, but it sets direction before FDA decisions and follow-on moves by state boards and payers. July 23-24 is where access to these four peptides starts getting decided.
Timeline3
Apr 16
Federal Register notice announced the Pharmacy Compounding Advisory Committee meeting and listed BPC-157, TB-500, KPV, and MOTS-c for Section 503A evaluation.
Jul 23
PCAC is scheduled to begin review of BPC-157, TB-500, KPV, and MOTS-c.
Jul 24
PCAC meeting continues into a second day as part of the July peptide compounding review.
1 comment
Apr 18